These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 26068778)

  • 1. CAR-modified T-cell therapy for cancer: an updated review.
    Haji-Fatahaliha M; Hosseini M; Akbarian A; Sadreddini S; Jadidi-Niaragh F; Yousefi M
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1339-49. PubMed ID: 26068778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
    Curran KJ; Pegram HJ; Brentjens RJ
    J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.
    Zhang Q; Li H; Yang J; Li L; Zhang B; Li J; Zheng J
    Curr Gene Ther; 2013 Feb; 13(1):65-70. PubMed ID: 23256743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
    Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
    Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
    Gilham DE; Debets R; Pule M; Hawkins RE; Abken H
    Trends Mol Med; 2012 Jul; 18(7):377-84. PubMed ID: 22613370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
    Shirasu N; Kuroki M
    Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
    Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
    Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
    Gross G; Eshhar Z
    Annu Rev Pharmacol Toxicol; 2016; 56():59-83. PubMed ID: 26738472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
    Miliotou AN; Papadopoulou LC
    Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Masked Chimeric Antigen Receptor for Tumor-Specific Activation.
    Han X; Bryson PD; Zhao Y; Cinay GE; Li S; Guo Y; Siriwon N; Wang P
    Mol Ther; 2017 Jan; 25(1):274-284. PubMed ID: 28129121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
    Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
    Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
    Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
    J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
    Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cell Therapy in Hematology.
    Ataca P; Arslan Ö
    Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
    Liu L; Sun M; Wang Z
    Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.